Drug intelligence / Profile preview

Xavertia

Development stage: Unknown
Lead developer: Innovis Pharma
Modality: Small Molecules
Administration: Oral

Overview

Xavertia is a generic anticoagulant medication containing the active ingredient rivaroxaban. It is a small molecule drug that acts as a direct, highly selective inhibitor of Factor Xa, a key protein in the blood coagulation cascade. By inhibiting Factor Xa, Xavertia prevents the conversion of prothrombin to thrombin, thereby reducing the formation of blood clots. It is marketed by Innovis Pharma in Greece and is indicated for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Brand names: Xavertia
Other names: rivaroxaban

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on Xavertia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xavertia.

Explore the full profile